Manuscripts
July 28, 2023
Multiple myeloma in adolescent and young adults: An ASCO CancerLinQ and SEER analysis
Clinical Lymphoma, Myeloma & Leukemia
Gibson S et al
May 23, 2023
Health data sharing perspectives of patients receiving care in CancerLinQ-participating oncology practices
JCO Oncology Practice
Jagsi R et al
March 26, 2023
Real-world big-data: Strengths and weaknesses of ASCO's CancerLinQ Discovery multiple myeloma dataset
American Journal of Hematology
DeStefano CB et al
February 22, 2023
Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer
PharmacoEconomics - Open
Verhoek A et al
January 10, 2023
Case studies for overcoming challenges in using big data in cancer
Cancer Research
Sweeney SM et al
January 10, 2023
Challenges to using big data in cancer
Cancer Research
Sweeney SM et al
August 10, 2022
Incidence of SARS-CoV-2 and subsequent mortality in a multi-site cohort of patients with cancer in the CancerLinQ Discovery database
JCO Oncology Practice
Ray E et al
June 3, 2022
Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data
Drugs - Real World Outcomes
Nieva J et al
May 1, 2022
Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology
Thanarajasingam G et al
Abstracts
October 27, 2023
Implementing a BRAF biomarker electronic clinical quality measure in CancerLinQ
ASCO Quality Care Symposium 2023
Drumheller C et al
June 2, 2023
A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.
ASCO Annual Meeting 2023
Avinash P B et al
June 2, 2023
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer
ASCO Annual Meeting 2023
Naidoo J et al
June 2, 2023
Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2-advanced breast cancer (aBC)
ASCO Annual Meeting 2023
Hathi D et al
June 2, 2023
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
ASCO Annual Meeting 2023
McKelvey B A et al
June 2, 2023
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations
ASCO Annual Meeting 2023
Gray J E et al
June 2, 2023
Pitfalls with analyses of real-world data: A look at ASCO’s CancerLinQ Discovery Multiple Myeloma dataset
ASCO Annual Meeting 2023
Shou K J et al
June 2, 2023
Treatment outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver
ASCO Annual Meeting 2023
Ryder A et al
June 2, 2023
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification
ASCO Annual Meeting 2023
Ryder A et al
